Aurobindo Pharma Share Price Rises After Q4 Revenue Growth
Aurobindo Pharma reported a consolidated revenue increase of 10.6% year-on-year, reaching Rs 8,382 crore in Q4 FY25.
Aurobindo Pharma's share price rose over 2% on Monday following the announcement of its Q4 FY25 results. The pharmaceutical giant reported a consolidated revenue increase of 10.6% year-on-year, reaching Rs 8,382 crore, surpassing Bloomberg's estimate of Rs 8,197 crore.
Despite a slight dip in net profit, which fell by 0.6% to Rs 903.5 crore due to higher interest costs, depreciation expenses, and increased tax liabilities, the company's overall performance was buoyed by revenue growth across its business segments. The Ebitda rose by 7% to Rs 1,792 crore, although it fell short of the estimated Rs 1,827 crore. The Ebitda margin narrowed slightly to 21.4% from 22%, against an estimated 22.3%.
Aurobindo Pharma's US formulations segment showed growth, with revenue increasing by 13.5% to Rs 4,072 crore. Similarly, the Europe formulations segment saw a rise of 17.2% year-on-year, reaching Rs 2,147 crore.
The company's net profit was impacted by a higher share of loss from associates and joint ventures, which amounted to Rs 32 crore compared to Rs 12 crore last year.
Aurobindo Pharma Share Price Today
The scrip rose as much as 2.20% to Rs 1,206 apiece. It pared gains to trade 2.01% higher at Rs 1,204 apiece, as of 09:47 a.m. This compares to a 0.81% advance in the NSE Nifty 50.
It has risen 0.69% in the last 12 months. Total traded volume so far in the day stood at 2.1 times its 30-day average. The relative strength index was at 51.
Out of 29 analysts tracking the company, 23 maintain a 'buy' rating, two recommend a 'hold' and four suggest 'sell', according to Bloomberg data. The average 12-month consensus price target implies an upside of 25.2%.
